Comparison · NCT00662831-d333cfec
Dalteparin vs Placebo: Number of Participants Who Died
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dalteparin vs Placebo: Number of Participants Who Died. Trial comparisons, record NCT00662831-d333cfec. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00662831-d333cfec
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0217 | 0.00849 | 0.0546 | wilson | |
| Risk in group 2 | 0.0326 | 0.0112 | 0.0915 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0109 | -0.0713 | 0.0283 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.667 | 0.152 | 2.92 | log | |
| Odds ratio, group 1 over group 2 | 0.659 | 0.144 | 3.01 | log | |
| Number needed to treat, for one fewer participant with the outcome on Dalteparin than on Placebo | 92 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dalteparin | Dalteparin 5000 International Units (IU) (0.2 mL) subcutaneously (s.c.) once daily for 24 weeks or early termination (ET). | 4 | 184 | OG000 |
| Group 2 | Placebo | Placebo (0.2 mL normal saline) administered s.c. once daily for 24 weeks or ET. | 3 | 92 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Who Died
- Description
- Time frame
- Week 24 (EOT) or early termination
- Population
- ITT population included all participants who were randomized.
Source ClinicalTrials.gov
Trial
- Title
- Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients
- NCT number
- NCT00662831
- Phases
- PHASE2, PHASE3
- Conditions
- Diabetic Foot Ulcer
- Interventions
- Fragmin/ Dalteparin Sodium, Placebo for Fragmin/ Dalteparin Sodium
- Lead sponsor
- Pfizer
- Results first posted
- 2012-01-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00662831?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00662831-d333cfec